SPONSOR

Peking University First Hospital

Total Trials

Recruiting

Phases

Phase 4, Phase 2, Phase 3, Phase 2

Conditions studied: Primary Aldosteronism Prostate Cancer Primary Cutaneous Lymphoma Coronary Microvascular Disease Antiphospholipid (aPL)-Positive Thrombocytopaenia Oligometastatic Disease Ureter Cancer Renal Pelvic Carcinoma Neoplasms

Peking University First Hospital is a clinical research sponsor with 17 registered studies on ClinicalTrials.gov, of which 17 are actively recruiting participants. Research covers conditions including Primary Aldosteronism, Prostate Cancer, Primary Cutaneous Lymphoma, Coronary Microvascular Disease.

The trial portfolio spans Phase 4, Phase 2, Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Peking University First Hospital

How many clinical trials has Peking University First Hospital sponsored?

ClinicalMetric currently tracks 17 clinical trials sponsored by Peking University First Hospital, of which 17 are actively recruiting participants. These trials cover conditions including Primary Aldosteronism, Prostate Cancer, Primary Cutaneous Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Peking University First Hospital research focus on?

Peking University First Hospital clinical trials span Primary Aldosteronism, Prostate Cancer, Primary Cutaneous Lymphoma, Coronary Microvascular Disease, Antiphospholipid (aPL)-Positive, and additional conditions. The research pipeline includes Phase 4, Phase 2, Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Peking University First Hospital clinical trial?

To participate in a Peking University First Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peking University First Hospital trials with current recruitment status updated daily.

Peking University First Hospital

Frequently Asked Questions — Peking University First Hospital

Clinical Trials by Peking University First Hospital

Multi-omics Studies of Primary Aldosteronism

Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer

TreAtments and outComes in paTients With prImary CutAneous Lymphoma

A Clinical Study of Fundus OCTA for the Identification of CMD

Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs

68Ga-P3 PET/CT Imaging in Prostate

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis

Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery

Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes

Repetitive Transcranial Magnetic Stimulation and Postoperative Neurocognitive Recovery

68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma

68Ga-BCMA PET/CT in Multiple Myeloma

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

Distribution of Mood and Personality Characteristics and Their Influence on Treatment Compliance